Baird lowered the firm’s price target on Soleno Therapeutics (SLNO) to $107 from $121 and keeps an Outperform rating on the shares. The firm updated its model after the company’s earnings preannouncement beat expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics: Sustained U.S. Vykat XR Outperformance and European Upside Support Buy Rating and $100 Target
- Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research
- Midday Fly By: Alphabet hits $4T market cap, Walmart to join Nasdaq-100
- Morning Movers: Sun Country jumps after deal to be bought by Allegiant
- Soleno Therapeutics reports preliminary Q4 revenue $90M-$92M, consensus $81.67M